Maturitas · 2026
Prescribing practices for menopausal hormone therapy in France in 2025: A national online survey (MENOPRAT).
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hardy Chloé, Gosset Anna, Rouchou Léa, Frantz Sandrine, Hocke Claude, Tremollieres Florence, Bernard Valérie
Аннотация
OBJECTIVES: This study was performed to provide an updated overview of menopause management among French gynaecologists in 2025, with a focus on prescribing practices for menopausal hormone therapy (MHT), perceived barriers, and the use of alternative therapies.
STUDY DESIGN: This national, cross-sectional, anonymous online survey was conducted between March and June 2025.
MAIN OUTCOME MEASURES: The primary outcome was the proportion of respondents prescribing MHT as first-line therapy for moderate to severe vasomotor symptoms (VMS) in women without contraindications. The secondary outcomes were physicians' perceptions assessed using 0-10 scales, barriers to prescribing, and the use of alternative therapies.
RESULTS: In total, 440 questionnaires were analysed. Overall, 76.4% of physicians reported prescribing MHT as first-line treatment for VMS. The median rating of 'comfort with prescribing' was 8.0 (interquartile range 7.0-9.0), and perceived benefit was high (median 9.0, interquartile range 8.0-10.0). The most frequently reported barriers were patients' hesitancy (59.8%), physicians' concern regarding elevated risks of breast cancer and cardiovascular events (34.8% and 29.5%, respectively). Alternative therapies were commonly used, mainly in cases of contraindication to or refusal of MHT; dietary supplements (70.0%), acupuncture (39.0%), and phytoestrogens (37.0%) were the most frequently prescribed. Finally, 67% of respondents expressed interest in additional training on MHT.
CONCLUSIONS: Despite strong perceived benefits and a high level of comfort with prescribing, one in four gynaecologists does not systematically offer MHT as first-line therapy for moderate to severe VMS. A gap persists between guidelines and real-life menopause care. Patient hesitancy and risk perceptions underline the need for improved education and decision-support tools.
STUDY DESIGN: This national, cross-sectional, anonymous online survey was conducted between March and June 2025.
MAIN OUTCOME MEASURES: The primary outcome was the proportion of respondents prescribing MHT as first-line therapy for moderate to severe vasomotor symptoms (VMS) in women without contraindications. The secondary outcomes were physicians' perceptions assessed using 0-10 scales, barriers to prescribing, and the use of alternative therapies.
RESULTS: In total, 440 questionnaires were analysed. Overall, 76.4% of physicians reported prescribing MHT as first-line treatment for VMS. The median rating of 'comfort with prescribing' was 8.0 (interquartile range 7.0-9.0), and perceived benefit was high (median 9.0, interquartile range 8.0-10.0). The most frequently reported barriers were patients' hesitancy (59.8%), physicians' concern regarding elevated risks of breast cancer and cardiovascular events (34.8% and 29.5%, respectively). Alternative therapies were commonly used, mainly in cases of contraindication to or refusal of MHT; dietary supplements (70.0%), acupuncture (39.0%), and phytoestrogens (37.0%) were the most frequently prescribed. Finally, 67% of respondents expressed interest in additional training on MHT.
CONCLUSIONS: Despite strong perceived benefits and a high level of comfort with prescribing, one in four gynaecologists does not systematically offer MHT as first-line therapy for moderate to severe VMS. A gap persists between guidelines and real-life menopause care. Patient hesitancy and risk perceptions underline the need for improved education and decision-support tools.